New Directions and Practice Impacting Recommendations in Multiple Sclerosis
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
CTAD Poster Shows Etalanetug Reduced Tau Pathology Biomarkers in Dominantly Inherited Alzheimer Disease
2
Alzheimer Trial PRImus-AD Tests Orally Available PRI-002 as New Treatment
3
Early Phase 3 Data Highlight Convenience and Feasibility of Self-Administered Alzheimer Agent Remternetug
4
Phase 3 Trial to Uncover Therapeutic Potential of 5-HT6 Antagonist Masupirdine to Treat Alzheimer Agitation
5
